4//SEC Filing
Panzara Michael A. 4
Accession 0000899243-21-007206
CIK 0001631574other
Filed
Feb 17, 7:00 PM ET
Accepted
Feb 18, 7:16 PM ET
Size
9.7 KB
Accession
0000899243-21-007206
Insider Transaction Report
Form 4
Panzara Michael A.
Franchise Lead, Neurology
Transactions
- Award
Ordinary Shares
2021-02-01+50,000→ 89,349 total - Sale
Ordinary Shares
2021-02-16$10.57/sh−2,929$30,960→ 86,420 total - Award
Share Option (right to buy)
2021-02-01+50,000→ 50,000 totalExercise: $10.48Exp: 2031-02-01→ Ordinary Shares (50,000 underlying)
Footnotes (4)
- [F1]Consists of restricted share units (RSUs). The RSUs vest in two equal installments on February 15, 2022 and February 15, 2023.
- [F2]On February 16, 2021, the reporting person sold 2,929 ordinary shares solely to cover taxes associated with the vesting of RSUs on February 15, 2021. These sales were made pursuant to a 10b5-1 Trading Plan.
- [F3]The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $10.47 to $10.58 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
- [F4]The option vests as to 50% of the shares on February 15, 2022 and 50% on February 15, 2023.
Documents
Issuer
Wave Life Sciences Ltd.
CIK 0001631574
Entity typeother
Related Parties
1- filerCIK 0001679039
Filing Metadata
- Form type
- 4
- Filed
- Feb 17, 7:00 PM ET
- Accepted
- Feb 18, 7:16 PM ET
- Size
- 9.7 KB